These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 35123183)

  • 1. A review on evolution of emerging SARS-CoV-2 variants based on spike glycoprotein.
    Ghosh N; Nandi S; Saha I
    Int Immunopharmacol; 2022 Apr; 105():108565. PubMed ID: 35123183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. V367F Mutation in SARS-CoV-2 Spike RBD Emerging during the Early Transmission Phase Enhances Viral Infectivity through Increased Human ACE2 Receptor Binding Affinity.
    Ou J; Zhou Z; Dai R; Zhang J; Zhao S; Wu X; Lan W; Ren Y; Cui L; Lan Q; Lu L; Seto D; Chodosh J; Wu J; Zhang G; Zhang Q
    J Virol; 2021 Jul; 95(16):e0061721. PubMed ID: 34105996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics.
    Barton MI; MacGowan SA; Kutuzov MA; Dushek O; Barton GJ; van der Merwe PA
    Elife; 2021 Aug; 10():. PubMed ID: 34435953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transformations, Lineage Comparisons, and Analysis of Down-to-Up Protomer States of Variants of the SARS-CoV-2 Prefusion Spike Protein, Including the UK Variant B.1.1.7.
    Peters MH; Bastidas O; Kokron DS; Henze CE
    Microbiol Spectr; 2021 Sep; 9(1):e0003021. PubMed ID: 34346753
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Computational modeling of the effect of five mutations on the structure of the ACE2 receptor and their correlation with infectivity and virulence of some emerged variants of SARS-CoV-2 suggests mechanisms of binding affinity dysregulation.
    Rodriguez JA; Gonzalez J; Arboleda-Bustos CE; Mendoza N; Martinez C; Pinzon A
    Chem Biol Interact; 2022 Dec; 368():110244. PubMed ID: 36336003
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolutionary and Phylogenetic Dynamics of SARS-CoV-2 Variants: A Genetic Comparative Study of Taiyuan and Wuhan Cities of China.
    Hussain B; Wu C
    Viruses; 2024 Jun; 16(6):. PubMed ID: 38932199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Corcern.
    Akkız H
    Front Med (Lausanne); 2022; 9():849217. PubMed ID: 35669924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of SARS-CoV-2 Variants B.1.617.1 (Kappa), B.1.617.2 (Delta), and B.1.618 by Cell Entry and Immune Evasion.
    Ren W; Ju X; Gong M; Lan J; Yu Y; Long Q; Kenney DJ; O'Connell AK; Zhang Y; Zhong J; Zhong G; Douam F; Wang X; Huang A; Zhang R; Ding Q
    mBio; 2022 Apr; 13(2):e0009922. PubMed ID: 35266815
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ten emerging SARS-CoV-2 spike variants exhibit variable infectivity, animal tropism, and antibody neutralization.
    Zhang L; Cui Z; Li Q; Wang B; Yu Y; Wu J; Nie J; Ding R; Wang H; Zhang Y; Liu S; Chen Z; He Y; Su X; Xu W; Huang W; Wang Y
    Commun Biol; 2021 Oct; 4(1):1196. PubMed ID: 34645933
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2 vaccine breakthrough infections (VBI) by Omicron variant (B.1.1.529) and consequences in structural and functional impact.
    Abduljaleel Z; Melebari S; Athar M; Dehlawi S; Udhaya Kumar S; Aziz SA; Dannoun AI; Malik SM; Thasleem J; George Priya Doss C
    Cell Signal; 2023 Sep; 109():110798. PubMed ID: 37423342
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern.
    Kovacech B; Fialova L; Filipcik P; Skrabana R; Zilkova M; Paulenka-Ivanovova N; Kovac A; Palova D; Rolkova GP; Tomkova K; Csokova NT; Markova K; Skrabanova M; Sinska K; Basheer N; Majerova P; Hanes J; Parrak V; Prcina M; Cehlar O; Cente M; Piestansky J; Fresser M; Novak M; Slavikova M; Borsova K; Cabanova V; Brejova B; Vinař T; Nosek J; Klempa B; Eyer L; Hönig V; Palus M; Ruzek D; Vyhlidalova T; Strakova P; Mrazkova B; Zudova D; Koubkova G; Novosadova V; Prochazka J; Sedlacek R; Zilka N; Kontsekova E
    EBioMedicine; 2022 Feb; 76():103818. PubMed ID: 35078012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structural Evaluation of the Spike Glycoprotein Variants on SARS-CoV-2 Transmission and Immune Evasion.
    Salleh MZ; Derrick JP; Deris ZZ
    Int J Mol Sci; 2021 Jul; 22(14):. PubMed ID: 34299045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Key Substitutions in the Spike Protein of SARS-CoV-2 Variants Can Predict Resistance to Monoclonal Antibodies, but Other Substitutions Can Modify the Effects.
    Lusvarghi S; Wang W; Herrup R; Neerukonda SN; Vassell R; Bentley L; Eakin AE; Erlandson KJ; Weiss CD
    J Virol; 2022 Jan; 96(1):e0111021. PubMed ID: 34668774
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
    Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
    Elife; 2020 Oct; 9():. PubMed ID: 33112236
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epistasis at the SARS-CoV-2 Receptor-Binding Domain Interface and the Propitiously Boring Implications for Vaccine Escape.
    Rochman ND; Faure G; Wolf YI; Freddolino PL; Zhang F; Koonin EV
    mBio; 2022 Apr; 13(2):e0013522. PubMed ID: 35289643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein.
    Kumar S; Thambiraja TS; Karuppanan K; Subramaniam G
    J Med Virol; 2022 Apr; 94(4):1641-1649. PubMed ID: 34914115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARS-CoV-2 variants.
    Wang Q; Ye SB; Zhou ZJ; Li JY; Lv JZ; Hu B; Yuan S; Qiu Y; Ge XY
    J Med Virol; 2023 Jan; 95(1):e28116. PubMed ID: 36056469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations and Evolution of the SARS-CoV-2 Spike Protein.
    Magazine N; Zhang T; Wu Y; McGee MC; Veggiani G; Huang W
    Viruses; 2022 Mar; 14(3):. PubMed ID: 35337047
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emerging mutation patterns in SARS-CoV-2 variants.
    Ostrov DA; Knox GW
    Biochem Biophys Res Commun; 2022 Jan; 586():87-92. PubMed ID: 34837837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.